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Report of depressive symptoms on waiting list
and mortality after liver and kidney
transplantation: a prospective cohort study
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Denis Castaing7, Bernard Charpentier8 and Bruno Falissard9
Abstract
Background: Little research has explored pre-transplantation psychological factors as predictors of outcome after
liver or kidney transplantation. Our objective is to determine whether report of depressive symptoms on waiting
list predicts outcome of liver and kidney transplantation.
Methods: Patients on waiting list for liver or kidney transplantation were classified for report or non-report of
depressive symptoms on waiting list. 339 were transplanted 6 months later on average, and followed prospectively.
The main outcome measures were graft failure and mortality 18 months post-transplantation.
Results: Among the 339 patients, 51.6% reported depressive symptoms on waiting list, 16.5% had a graft failure
and 7.4% died post-transplantation.
Report of depressive symptoms on waiting list predicted a 3 to 4-fold decreased risk of graft failure and mortality
18-months post-transplantation, independently from age, gender, current cigarette smoking, anxiety symptoms,
main primary diagnosis, UNOS score, number of comorbid diagnoses and history of transplantation. Data were
consistent for liver and kidney transplantations. Other baseline predictive factors were: for graft failure, the main
primary diagnosis and a shorter length since this diagnosis, and for mortality, older age, male gender and the main
primary diagnosis.
Conclusion: Further studies are needed to understand the underlying mechanisms of the association between
report of depressive symptoms on waiting list and decreased risk of graft failure and mortality after transplantation.
Keywords: depressive symptoms, self-assessment, transplantation, liver, kidney, outcome
Background
The growing population of patients who have survived
liver and kidney transplantation [1,2] has intensified the
need to identify risk factors for less favourable outcomes
such as graft failure and mortality.
Some risk factors for graft failure and mortality are
related to the transplantation and the post-transplantation
period. Others are already known for earlier stages, when
transplantation candidates are on waiting list. These are
recipient characteristics, such as age, gender, diagnosis of
primary medical disease, United Network for Organ Shar-
ing (UNOS) priority status, cigarette smoking status or
self-reported medication nonadherence and depressive
symptoms [3-9].
Whether or not the report of depressive symptoms on
waiting list by future recipients predicts liver and kidney
transplantation outcomes remains uncertain, since the
three prospective studies available for liver [8,10] and for
kidney transplantation [4] failed to show significant results,
probably because of small sample sizes. Of note, other stu-
dies in the field of transplantation showed divergent
results: two studies in heart transplantation showed either
a poorer outcome in patients with pre-transplantation
depressive symptoms [11] or non-significant results [12]
whereas a study in lung transplantation [13] showed a
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better one-year post-transplantation outcome for patients
who were depressed before transplantation.
The paucity of literature assessing whether depressive
symptom report on waiting list is a risk factor for solid
organ transplantation outcome is surprising considering
the extraordinary stress associated with organ failure and
terminal illness, the complex process involved in selecting
transplant candidates for scarce organs, the period of wait-
ing for an available donor transplant, the uncertainty of
surviving the surgery and any postoperative complications,
and the anticipated complications of immunosuppressant
treatment.
Our hypothesis is that a high level of report of depres-
sive symptoms on waiting list predicts poor outcome post-
transplantation. Our objective was to determine whether
report of depressive symptoms on waiting list for liver or
kidney transplantation would be associated with transplan-
tation outcome.
Methods
Study design and population
PSYGREF is a prospective longitudinal observational
cohort of adult patients. Its main objective is to assess the
relationship between psychological variables and outcome
of liver and kidney transplantation. Patients were assessed
on waiting list from September 1, 2002 in the three kidney
and liver transplantation centres in the southern area of
Paris, France. The present analysis was conducted on
patients transplanted before February 2006 and followed
up until July 2007, and focused on report of depressive
symptoms (Figure 1).
The PSYGREF procedures were approved by the ethics
committee of the University Hospital of Bicetre, the insti-
tutional review board of the Clinical Research Department
of Paris. Data were used according to the standard regula-
tions of the French network for transplantation and for
the preservation of patient anonymity and privacy. On
account of ethical considerations and in order to avoid
bias arising from additional visits, PSYGREF procedures
and assessments were conducted when patients had an
appointment at the transplantation centre for usual medi-
cal visits.
After inclusion on waiting list in the liver and kidney
transplantation centres of Paris-XI and XII universities
(Centre Hepato-Biliaire of Paul Brousse Hospital, Nephrol-
ogy Departments of Bicetre and Mondor Hospitals), the
medical investigator offered patients the possibility of
entering the PSYGREF cohort. Eligible participants were
at least 18 years old and had sufficient French language
proficiency to complete the assessments. Patients unable
to communicate or complete questionnaires, or referred
for an emergency transplantation were excluded. Patients
were informed that their psychological results would not
be known by the transplantation staff. Each patient
provided written informed consent. Psychological assess-
ments were conducted by a trained clinical psychologist,
blind to medical data. The medical staff was also blind to
psychological data. PSYGREF medical data were collected
independently from the psychologist interview. They were
validated by the PSYGREF scientific board.
Number of patients at each step are shown in figure 1
The median length between baseline assessment and
transplantation was 28 weeks (interquartile range 10-60).
Baseline assessment
Because many patients were accessible for only brief
periods of time, brief instruments were selected.
The standardized self-administered Beck Depression
Inventory - Short form (Short-BDI) [14] was used to assess
depressive symptoms. The Short-BDI is a brief 13-item
self-report inventory, comprising few somatic items,
designed and recommended for assessing report of depres-
sive symptoms in patients with medical illnesses [15]. Each
item is scored on a 4-point likert scale from 0 to 3. It takes
approximately 3-5 min to complete. Cut-off scores for
severity of depressive symptoms are available [16]: none or
minimal 0[1-3]; mild [4-7]; moderate [8-15]; severe [16
and above]. The binary variable “Short-BDI score less than
4 (yes/no)” was the main explanatory variable. Report of
depressive symptoms was thus defined by a short-BDI
score of 4 or more.
The 20-item self-report State Trait Anxiety Inventory
(STAI) [17], a self-report measure of current anxiety
symptoms, focusing on another specific facet of emotional
distress, was used to determine whether anxiety and
depressive symptoms are differentially related to trans-
plantation outcomes. Since STAI scores were normally
distributed, the raw STAI score was used at the early stage
of the univariate analysis as a secondary explanatory
variable.
Ongoing mental health care, comprising either current
psychological or psychiatric treatment or psychotropic
drug treatment, was also recorded as a categorical variable
(yes/no).
Outcome ascertainment
The 339 transplanted patients were assessed 3 and 18
months post-transplantation for outcome variables. None
of the 339 patients was lost to follow-up (Figure 1).
The main outcome measure was 18-month graft survi-
val, i.e. absence of graft failure. It was recorded as a cate-
gorical variable (yes/no). Graft failure was defined either
by death or irreversible graft loss. Irreversible graft loss
was defined as retransplantation for liver grafts and return
to chronic dialysis for kidney grafts.
The secondary outcome measure was 18-month
patient survival, i.e. absence of death. It was recorded as
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793 adults on waiting list for liver or kidney transplantation 
 between Sept 2002 and Nov 2005 
      163 not enrolled 
                 25 eligible but declined consent 
48 were unable to communicate or fill 
questionnaires 
                                                    90 researcher unavailable  
to enrol patients # 
27 enrolled but pretransplantation  
           assessment not available 
  
603 enrolled in the PSYGREF cohort  
who completed Short-BDI and STAI assessment on waiting list
       
       24 died 
            7 lost to follow-up           
       233 not transplanted  
339 patients transplanted between Oct 2002 and January 2006 (152/187)* 
Short-BDI less than 4: 164 (76/88)*    Short-BDI 4 and more: 175 (76/99)*
 
  
3 months post-transplantation 
 Alive: 154 (68/86)*             Alive: 171 (74/97)* 
Graft survival: 147 (65/82)*     Graft survival: 168 (73/95)* 
Lost to follow-up: none 
18 month post-transplantation  
      Alive: 145 (63/82)*                                 Alive: 167 (70/97)*  
Graft survival: 137 (61/76)*               Graft survival: 162 (69/93)* 
Lost to follow-up: none 
Figure 1 Flow of participation and number of events. # Only one half-time researcher per center sought consent for participation and
assessed patients. When this researcher was unavailable, new patients could not be enrolled. *Numbers of patients are given for the whole
sample and for liver and kidney transplantation into brackets (liver/kidney).
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a categorical variable (yes/no). Deaths from all causes
were ascertained by active follow-up through transplan-
tation centre, medical centres that referred patients to
the transplantation centre and family physicians.
Data analysis
Statistical analyses were performed using the R 2.4.0
package [18]. All tests were two-tailed.
The analysis strategy was defined a priori, based on
the main objective of the analysis, which was to deter-
mine whether report of depressive symptoms by patients
on waiting list would be associated with transplantation
outcome 18-months post-transplantation.
Bivariate and multivariate analyses adjusting for other
risk factors were performed. Kaplan-Meier plots were con-
structed to illustrate the association between baseline
characteristics and event-free survival. For the primary
analysis, logistic models were preferred to Cox propor-
tional hazards models to avoid the issue of discrepancies
between short-term and long-term survival. Usual regres-
sion diagnosis procedures were performed. No colinearity
was evidenced among covariates. Information on baseline
covariates was more than 99% complete. No imputation
was performed.
In order to select explanatory variables in logistic mod-
els, two series of multivariate models were designed. The
first was based on variables evidenced in the literature
(age, gender, diagnosis of primary medical disease, UNOS
priority status, number of comorbid medical diseases and
cigarette smoking). The second was a stepwise logistic
regression model, which minimized the Akaike Informa-
tion Criterion (AIC). This particular method penalizes
over-parameterization, variables being retained if the
model improves enough to balance the increasing number
of parameters. Since results of both models were similar,
we chose to show the stepwise modelling strategy.
The following baseline variables were considered for
inclusion in the models: age (expressed as age in years/
10), gender, education (higher secondary/university: yes/
no), married/cohabiting status (yes/no), current leisure
activities (yes/no), current professional activity (yes/no),
duration since the main primary medical diagnosis (<1,
1-5, 5-10, >10 years), number of comorbid medical
diseases, previous transplantation (yes/no), dual trans-
plantation (yes/no), current cigarette smoking (daily/
occasional/no), UNOS score (1: emergency transplanta-
tion; 2: continuous hospitalization in an acute care bed
for at least 5 days; 3: ongoing interactions with health
care system without continuous hospitalization; 4: at
home and functioning normally), STAI score and Short-
BDI score (report of depressive symptoms: short-BDI
score of 4 or more). The main primary diagnoses (glo-
merulopathies, tubulo-interstitial, vascular or other
nephropathies for kidney transplantation; non-cholestatic
cirrhosis, hepato-cellular carcinoma, metabolic diseases
or other liver diseases for liver transplantation) were
forced into all models.
The final model assessed the association of report of
depressive symptoms with 18-month graft failure in the
presence of the selected covariables.
Similar analyses were performed for patient survival,
the secondary endpoint.
Regarding depression scores, the same analyses using a
Short-BDI cut-off score of 7, corresponding to the
higher quartile of Short-BDI scores were also performed.
Results
Baseline pre-transplantation characteristics
The 339 transplanted patients were 48 years old on aver-
age (sd = 12). 41.3% were females. 20.4% were current
daily smokers, 47.8% had a higher secondary or university
qualification, 69.9% were married or cohabiting, 25.4% had
a current professional activity and 60.8% reported current
leisure activities.
The main primary medical diagnoses were: non chole-
static cirrhosis (mainly viral and alcoholic) (38.2%), hepa-
tocellular carcinoma (28.3%), cholestatic cirrhosis (12.5%),
metabolic disorders (19.7%), others (1.3%) for the 152 liver
transplantations; and primary glomerulopathies (46.5%),
tubulo-interstitial (11.2%), vascular (17.6%) and other
nephropathies (24.6%) for the 187 kidney transplantations.
Regarding UNOS score at baseline, 20.9% of patients
scored 2, 75.5% scored 3 and 3.5% scored 4.
The median Short-BDI score at baseline was 4 (mini-
mum: 0, maximum: 25, interquartile range: 2-7). The
Short-BDI score mean (sd) was 4.8(4.1). 175 (51.6%)
patients reported depressive symptoms (Short-BDI score
of 4 or more), including 106(31,3%) with mild depressive
symptoms, 64(18,9%) moderate and 5(1,5%) severe. 164
(48.3%) patients did not report depressive symptoms
(Short-BDI score less than 4). The median STAI score was
36. Its mean (sd) was 37.2(10.3). STAI and Short-BDI
scores were correlated (Pearson coefficient = 0.6).
As compared to patients who did not report depressive
symptoms, patients who did were younger, more fre-
quently females, living alone, daily cigarette smokers, they
had a lower educational status, were less frequently work-
ing and less frequently had leisure activities (table 1). They
were not significantly different regarding the likelihood of
being transplanted (57.5% among patients who did not
report depressive symptoms vs 54.0% among those who
did (p = 0.38)), the transplanted organ (kidney/liver),
UNOS score, the main primary diagnoses and length since
this diagnosis (table 1). Moreover, patients who did and
did not report depressive symptoms at baseline did not
differ in terms of ongoing mental health care at some time
during the study (respectively 9.9% and 5.7%; chi-squared:
p = 0.09).
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Transplantation characteristics
Comparisons of the 339 transplanted patients on the
transplantation characteristics showed no significant dif-
ferences between individuals who did and those who did
not report depressive symptoms at baseline: number of
weeks between baseline assessment and transplantation
(Wilcoxon: p = 0.68), number of years of dialysis for
kidney transplantation (median: 3 years among patients
who did report depressive symptoms vs 2.5 years among
those who did not, Mann&Whitney W = 4322, p-value
= 0.92), frequency of living donors (19.4% among
patients who did report depressive symptoms vs 19.5%
among those who did, chi-squared: p = 0.98), frequency
of surgical repairs (16.8% among patients who did report
depressive symptoms vs 19.5% among those who did
not, chi-squared: p = 0.51), median length of hospitaliza-
tion for transplantation (25 days among patients who
did report depressive symptoms vs 24 days among those
who did not, Wilcoxon: p = 0.39), and number of
immuno-suppressants recorded at time of discharge
from hospital following transplantation (chi-squared:
p = 0.66).
Table 1 Baseline socio-demographic, psychometric and medical characteristics in « report of depressive symptoms »
(short-BDI score of 4 or more) and « non-report of depressive symptoms » (short-BDI score less than 4) subgroups at
baseline
Baseline characteristics Non-report
of depressive symptoms
(n = 164)
Report
of depressive symptoms
(n = 175)
Statistics p
Socio-demographic
Age (years) (m(sd)) 48.7 (12.3) 46.0 (11.2) t (337df) = 2.1 0.03
Female n (%) 56 (34.1%) 84 (48.0%) Chi2 (1df) = 6.7 0.01
Higher secondary/university education n (%) 88 (53.7%) 74 (42.3%) Chi2 (1df) = 4.4 0.04
Married/cohabiting n (%) 122 (74.4%) 115 (65.7%) Chi2 (1df) = 3.0 0.08
Current professional activity n (%) 50 (30.5%) 36 (20.6%) Chi2 (1df) = 4.4 0.04
Current leisure activities n (%) 117 (71.8%) 88 (50.6%) Chi2 (1df) = 15.9 0.0007
Psychometric
STAI (m(sd)) 31.66 (7.24) 42.38 (10.04) t (337df) = -11.2 < 10 -4
Medical data
Main primary diagnosis Chi2 (7df) = 8.72 0.27
Glomerulopathies n (%) 35 (21.3%) 52 (29.7%)
Tubulointerstitial nephropathies n (%) 8 (4.9%) 13 (7.4%)
Vascular nephropathies n (%) 18 (11.0%) 15 (8.6%)
Other nephropathies n (%) 27 (16.5%) 19 (10.9%)
Non cholestatic cirrhosis n (%) 24 (14.6%) 34 (19.4%)
Hepatocellular carcinoma n (%) 24 (14.6%) 19 (10.9%)
Metabolic diseases n (%) 17 (10.4%) 13 (7.4%)
Other liver diseases n (%) 11 (6.7%) 10 (5.7%)
Length since the main primary diagnosis Chi2 (3df) = 2.0 0.56
<1 year n (%) 10 (6.1%) 18 (10.3%)
1 to 5 years n (%) 58 (35.4%) 59 (33.9%)
5 to 10 years n (%) 38 (23.2%) 37 (21.3%)
>10 years n (%) 58 (35.4%) 60 (34.5%)
UNOS score Chi2 (2df) = 5.4 0.07
2 n (%) 41 (25.0%) 30 (17.1%)
3 n (%) 120 (73.2%) 136 (77.7%)
4 n (%) 3 (1.8%) 9 (5.1%)
Current cigarette smoking Chi2 (2df) = 13.05 0.001
No n (%) 134 (81.7%) 117 (66.9%)
Occasional n (%) 10 (6.1%) 9 (5.1%)
Daily n (%) 20 (12.2%) 49 (28.0%)
Patients were classified into two groups:
“Non-report of depressive symptoms” for those with a short-BDI score less than 4,
“Report of depressive symptoms” for those with a short-BDI score of 4 or more.
STAI: State Trait Anxiety Inventory
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Outcomes
Graft and patient survival rates (Table 2) were obtained
for all transplanted patients. Mortality was due to infec-
tion (n = 10), acute liver failure (n = 5), recurrence of the
initial disease (n = 2), cardio-vascular causes (n = 2) for
liver transplantation, and infection (n = 5), graft rejection
(n = 1) and cardio-vascular causes (n = 2) for kidney
transplantation.
Bivariate analyses
Patients who did report depressive symptoms at baseline
had lower rates of graft failure and mortality than those
who did not (table 2). Figure 2 shows Kaplan-Meier
curves for 18-month graft survival according to report of
depressive symptoms at baseline.
7.4% of patients had graft failure among individuals
who did report depressive symptoms at baseline com-
pared to 16.5% among those who did not (OR, 0.41; 95%
CI, 0.20-0.82; p = 0.01) (table 3). The other baseline char-
acteristics were not significantly associated with 18-
month graft failure.
4.6% of patients died among those who did report
depressive symptoms at baseline compared to 11.6%
among those who did not (OR, 0.37; 95%CI, 0.16-0.88;
p = 0.02) (table 3). Older age (p = 0.02) and male gender
(p < 0.01) were also significantly associated with 18-
month mortality.
No significant effect of depressive symptom intensity
was shown either on 18-month graft survival or patient
survival.
Eleven of the thirteen Short-BDI items contributed to
results obtained on its total score (sadness OR 0.2, dissa-
tisfaction OR 0.36, self-image change OR 0.45, social
withdrawal OR 0.49, anorexia OR 0.54, self-dislike OR
0.59, pessimism OR 0.68, work difficulty OR 0.85, sense
of failure OR 0.87, guilt OR 0.93, self-harm OR 0.94,
fatigability OR 1.11 and indecisiveness OR 1.28), ruling
out the hypothesis that the association between graft sur-
vival and report of depressive symptoms might be related
to specific individual items.
Using a Short-BDI cut-off score of 7 corresponding to
the highest quartile of Short-BDI scores, the following
results were shown. 6.67% of patients (n = 6) had a graft
failure among the 90 individuals with a Short-BDI score
higher than 7 at baseline, compared to 13.65% (n = 34)
among the 249 others (OR, 0.45; 95%CI, 0.18 -1.12; p =
0.08). 3.33% of patients (n = 3) died among individuals
with a Short-BDI score higher than 7 at baseline, com-
pared to 9.64% (n = 24) among the others (OR, 0.32; 95%
CI, 0.09-1.1; p = 0.07).
Baseline STAI scores were not associated with graft
failure (OR, 0.98; 95%CI, 0.94-1.01; p = 0.15) or mortal-
ity (OR, 0.99; 95%CI, 0.95-1.03; p = 0.50).
Multivariate analyses
Logistic regressions adjusted for liver/kidney transplanta-
tion also showed that individuals who did report depres-
sive symptoms at baseline had lower rates of graft failure
than those who did not (table 3). Results were consistent
in the kidney subgroup (OR, 0.30; 95%CI, 0.09-1.43; p =
0.09) and the liver subgroup (OR, 0.42; 95%CI, 0.15-1.16;
p = 0.07).
Logistic regressions adjusted for liver/kidney trans-
plantation evidenced similar results for all-cause mortal-
ity (table 3).
After adjusting for confounding parameters using a
stepwise logistic regression, the association between
report of depressive symptoms and transplantation out-
come remained significant: 18-month graft failure was
independently predicted not only by the report of depres-
sive symptoms on waiting list, but also by the main pri-
mary diagnosis and a shorter length since this diagnosis
(tables 3 and 4); 18-month post-transplantation mortality
was independently predicted not only by the report of
depressive symptoms on waiting list, but also by the
main primary diagnosis, older age and male gender
(tables 3 and 5). Other variables did not significantly pre-
dict graft failure or mortality (table 4 and 5).
Using a Short-BDI cut-off score of 7 corresponding to
the higher quartile, after adjusting for confounding para-
meters using multiple logistic regressions, the association
between depressive symptoms and 18-month transplan-
tation outcome showed similar odds ratios and remained
almost significant (graft failure: OR, 0.42; 95%CI, 0.16-
1.09; p = 0.07; mortality: OR, 0.22; 95%CI, 0.04-1.06;
p = 0.06).
Results of multivariate analyses for 3-month graft fail-
ure and mortality were in line with those for 18-month
Table 2 Rates of graft failure and all-cause mortality, in patients who did and did not report depressive symptoms at
baseline
Non-report
of depressive symptoms
(n = 164)
Report
of depressive symptoms
(n = 175)
All Liver
(n = 76)
Kidney
(n = 88)
All Liver
(n = 76)
Kidney
(n = 99)
18-month graft failure % 16.5% 19.7% 13.6% 7.4% 9.2% 6.1%
18-month all-cause mortality % 11.6% 17.1% 6.8% 4.6% 7.9% 2%
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failure, although not always significant because of the
smaller number of events recorded at this time (Figure 1).
Discussion
About one patient out of two of the cohort reports
depressive symptoms on waiting-list for kidney or liver
transplantation. These symptoms were mainly of mild
intensity, ant to a lesser extent, of moderate intensity.
Although lower from those reported in general popula-
tion, this result is coherent with those of the literature
about report of depressive symptoms on waiting list for
kidney [4,19,20] or liver [21-25] transplantation. In a con-
text of knowledge pertaining to organ scarcity and wait-
ing list demand, social desirability might lead transplant
candidates to under-report the depressive symptoms they
are experiencing in order to present themselves as better
candidates for transplantation [26]. The specificity of our
results regarding report of depressive symptoms as com-
pared to anxiety symptoms suggests that anxiety, but not
depressive symptoms may be acceptable from a patient
and society point of view in the context of waiting for a
solid organ transplantation.
This study shows that report of depressive symptoms
on waiting list predicted a 3 to 4-fold decreased risk of
graft failure and mortality 18-months post-transplanta-
tion. This risk factor is independent from other risk fac-
tors such as age, gender, main primary diagnosis and
length since this diagnosis. Of note, the risk of death is 3
to 4 times lower for patients who report depressive symp-
toms on waiting list, suggesting the clinical relevance of
this association. Furthermore, data are consistent for liver
and kidney transplantations despite differences between
these two subgroups for socio-demographic and medical
factors. Moreover, using a Short-BDI cut-off score of 7,
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Figure 2 Cumulative incidence of graft survival based on report of depressive symptoms on waiting list. Patients were classified into
two groups: “Non-report of depressive symptoms” for those with a short-BDI score less than 4. “Report of depressive symptoms” for those with a
short-BDI score of 4 or more.
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corresponding to the higher quartile, the association
between depressive symptoms and 18-month transplanta-
tion outcome showed similar odds ratios and remained
almost significant despite small sample sizes. Thus, this
result suggests a more general association.
This study is the first prospective cohort study in the
field of liver and kidney transplantation showing an asso-
ciation between report of depressive symptoms on wait-
ing list and post-transplantation outcome, since the three
previous prospective studies [4,8,9] in this field failed to
show significant associations.
The four other prospective studies in the field of solid
organ transplantation showed divergent results. One
study [12] in heart transplantation was non-conclusive.
Another one [11] in heart transplantation also based on
self-report of depression showed contradictory results as
compared to ours. However, it was conducted in a small
subgroup of 57 patients with a specific cardiopathy. And
the third one [13] in lung transplantation showed results
similar to ours, i.e. a better one-year post-transplantation
outcome for patients who had a psychiatric history of
depression before transplantation. Recently, our study [9]
showed that depressive symptoms 3 months post-liver
transplantation and an increase in depressive symptoms
between the waiting list and post-liver transplantation
periods are associated with an increased risk of long-
term mortality. The results of the present study, which
show that report of depressive symptoms on waiting-list
predicted a 3 to 4-fold decreased risk of graft failure and
mortality 18-months post-transplantation, are somewhat
different, but compatible with the previous ones. Indeed,
the depression score increase between pre and post-
transplantation is favored by low pre-transplantation
scores. Moreover, the impact of social desirability could
explain this difference: whereas social desirability is high
in waiting-list, explaining low depression scores and the
present association, social desirability is not relevant any-
more in the post-transplantation period.
The association of depression with medical outcome
has been studied in other fields than transplantation,
especially cardio-vascular diseases. Even if almost half of
the 57 studies reviewed by Wulsin et al (1999) [27] failed
Table 4 Multivariate model predicting 18-month graft failure
Baseline Predictor Odds Ratio Coefficient
(95% CI)
P value P value for
overall test
Report of depressive symptoms (versus non-report) 0.37 [0.17; 0.78] 0.01
Male (vs female) 1.98 [0.91; 4.30] 0.08
Age (10 years more) 1.39 [1.00; 1.93] 0.05
Main primary diagnosis 0.04§
Non cholestatic cirrhosis 1.98 [0.67; 5.89] 0.22
Hepatocellular carcinoma 0.46 [0.14; 1.45] 0.19
Metabolic disorders 1.73 [0.58; 5.19] 0.33
Others liver diseases 2.67 [1.24; 5.72] 0.01
Glomerulopathies 1.21 [0.58; 2.54] 0.61
Tubulo-interstitial nephropathies 1.37 [0.41; 4.61] 0.61
Vascular nephropathies 0.33 [0.08; 1.28] 0.11
Others nephropathies 0.44 [0.14; 1.38] 0.16
Length since the main primary diagnosis * * 0.005§
<1 year 1.41 [0.61; 3.28] 0.43
1 to 5 years 0.34 [0.17; 0.70] 0.003
5 to 10 years 1.12 [0.57; 2.22] 0.74
>10 years 1.86 [1.03; 3.37] 0.04
OR, Odds Ratio for 18-month graft failure.
CI, Confidence Interval.
Table 3 Univariate and multivariate effects of “report of
depressive symptoms” at baseline on 18-month
outcomes
Odds Ratio (95% CI)* p
Non-adjusted univariate analysis
Graft failure 0.41 [0.20; 0.82] 0.01
Mortality 0.37 [0.16; 0.88] 0.02
Analysis adjusted for liver/kidney transplantation
Graft failure 0.40 [0.20; 0.83] 0.01
Mortality 0.37 [0.16; 0.88] 0.02
Multivariate stepwise logistic regression
Graft failure § 0.37 [0.17; 0.78] 0.01
Mortality §§ 0.25 [0.08; 0.83] 0.02
* Odds ratio for comparison with the « non-report of depressive symptoms»
subgroup.
CI indicates confidence interval.
§ Adjustment for: age, gender, main primary diagnosis and length since this
diagnosis.
§§ Adjustment for: age, gender, main primary diagnosis, length since this
diagnosis, history of transplantation and STAI score.
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to show any association between depressive symptoms
and mortality, several published studies showed that
major depression is associated with poorer outcome of
medical disorders. Our results are at odds with this litera-
ture, which however is controversial, since it failed to
show that treating major depression can improve out-
come of medical disorders, especially cardio-vascular dis-
eases [28]. Three major points may explain this
discrepancy. First, a publication bias may exist, penalising
results similar to ours. Secondly, we focused on report of
depressive symptoms and not on major depressive epi-
sodes as evaluated by clinicians with psychiatric inter-
views, which are assessed in a large number of published
studies. Last but not least, in most studies showing an
association between depression and poorer outcome,
depressive symptoms were assessed during or just after
an acute medical episode [29,30]. In contrast, our study
and the Woodman transplantation study [13] assessed
depressive symptoms very early in the process of trans-
plantation, i.e. at the beginning of the waiting list period,
in the specific context of transplantation candidacy invol-
ving social desirability. Yet those other studies are of
heart attack, which are indeed acute episodes. Emotional
response in the case of those waiting for transplants is a
very different case, where there is not an acute episode
but a long trajectory of increasingly severe illness and the
prospect of death without a transplant.
There is scope for generalising the results of this study
on the basis of its main strengths. First, we were able to
trace, 18 months post-transplantation, all transplanted
subjects from a fairly large cohort of 339 patients who
were not medically selected for health status at the time
of initial assessment. In addition, many of our results
are in line with the literature, not only in term of report
of depressive symptoms [21-24], but also in terms of
post-transplantation patient and graft survival
[2,6,24,31-35], causes of death [2,31,32,34,36] and pre-
dictive factors of transplantation outcome [3-7]. More-
over, the major strength of this study is that the
assessment of depressive symptoms took place not a few
days before transplantation, but 6 months earlier on
average. This is specific to this study as compared to
other available studies in the field of transplantation
[4,10-13].
Nevertheless, the present study has some limitations.
We failed to show a relationship between the severity of
depressive symptoms reported on waiting list and trans-
plantation outcome. Any correlation would have argued
for a causal relationship between these two variables.
Importantly, the results of the present study do not
address the risks associated with clinical depression but
focus on the risk associated with self-report of depressive
symptoms. Furthermore, our sample, recruited in 3
transplantation centers, may not be representative of all
patients on waiting list for liver or kidney transplantation.
And it cannot be ruled out that they may be explained by
residual confounding variables, such as non-measured
medical characteristics for example.
Table 5 Multivariate model predicting 18-month mortality
Baseline Predictor Odds Ratio Coefficient (95% CI) P value P value for overall test
Report of depressive symptoms (versus non-report) 0.25 [0.08 ; 0.83] 0.02
STAI 1.05 [0.99 ; 1.11] 0.14
Male (vs female) 9.03 [2.38 ; 34.22] 0.001
Age (10 years more) 1.91 [1.22 ; 3.01] 0.005
Main primary diagnosis 0.01 §
Non cholestatic cirrhosis 3.07 [0.81 ; 11.66] 0.10
Hepatocellular carcinoma 0.54 [0.15 ; 1.95] 0.35
Metabolic disorders 2.42 [0.63 ; 9.23] 0.20
Others liver diseases 4.98 [1.87 ; 13.25] 0.001
Glomerulopathies 0.58 [0.18 ; 1.82] 0.35
Tubulo-interstitial nephropathies 0.74 [0.09 ; 5.98] 0.78
Vascular nephropathies 0.23 [0.03 ; 1.57] 0.13
Others nephropathies 0.52 [0.12 ; 2.15] 0.36
Length since the main primary diagnosis * * 0.09 §
<1 year 1.14 [0.38 ; 3.45] 0.81
1 to 5 years 0.36 [0.15 ; 0.87] 0.02
5 to 10 years 1.77 [0.75 ; 4.18] 0.19
>10 years 1.38 [0.55 ; 3.47] 0.50
History of transplantation 2.98 [0.73 ; 12.15] 0.13
OR, Odds Ratio for 18-month mortality.
CI, Confidence Interval.
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The mechanisms by which our main result could be
explained require further studies. An hypothesis could be
that recipients experiencing depressive symptoms on wait-
ing list may be better able to identify and face later psycho-
logical difficulties, and thus be better prepared to cope with
the significant stressors that occur post-transplantation
[13]. Another relevant hypothesis could be that report of
lack of depressive symptoms on waiting list may be asso-
ciated with report of medication non-adherence on waiting
list, which has been shown to be associated with a poorer
prognosis of transplantation [8]. The role of denial might
also be relevant: those who do not acknowledge depression
might also be more likely to deny physical symptoms
and therefore not seek help when needed or adhere to
medications.
Conclusion
In summary, our results show that patients who report
depressive symptoms on waiting list several months before
transplantation have a three-fold decreased risk of graft
failure and mortality 18-months after kidney or liver trans-
plantation. This risk factor is independent from other
established demographic and medical risk factors. Further
studies are needed to replicate this result and assess its
underlying mechanisms.
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